Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...

Analysts are intrested in these 5 stocks: ( ($MRK) ), ( ($REGN) ), ( ($CLRB) ), ( ($HUMA) ) and ( ($FL) ). Here is a ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

MSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

With annual revenue of $63.9 billion and a robust research pipeline, Merck continues to demonstrate its commitment to innovation in healthcare. This marks the first instance of a KEYTRUDA-based ...

Find insight on Merck and Exelixis in the latest Market Talks covering Health Care.

Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), IBM Corp. (IBM) and ...

In October, Merck announced that the Phase 3 KEYNOTE-689 trial of Keytruda, as a perioperative treatment for patients newly diagnosed with stage III or IVA, resected, locally advanced head and ...

With annual revenue of $63.9 billion and a robust research pipeline, Merck continues to demonstrate its commitment to innovation in healthcare. This marks the first instance of a KEYTRUDA-based ...